Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10173338
• 负责人: Mary Sano
• 金额: $ 42.38万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10173338
• 关键词: African American; Age; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer’s disease biomarker; Amyloid; Amyloidosis; Asians; Autopsy; Biological Markers; Blood Vessels; Brain; Budgets; Cerebrospinal Fluid; Classification; Clinical; Clinical Trials; Cognition; Communities; Data; Data Collection; Data Set; Detection; Diagnosis; Diagnostic; Diagnostics Research; Disease; Exhibits; High Prevalence; Hispanics; Image; Impaired cognition; Incidence; Individual; Intervention; Literature; Low Prevalence; Magnetic Resonance Imaging; Measures; Memory impairment; Minority; Minority Participation; Nerve Degeneration; Neurofibrillary Tangles; Not Hispanic or Latino; Observation in research; Participant; Pathology; Population; Population Heterogeneity; Positron-Emission Tomography; Prevalence; Protocols documentation; Race; Research; Resources; Senile Plaques; Sex Distribution; Site; Specific qualifier value; Standardization; Tauopathies; Underserved Population; United States; United States National Institutes of Health; Vascular Diseases; apolipoprotein E-4; biomarker evaluation; carrier status; cohort; comorbidity; data exchange; imaging biomarker; in vivo; neuroimaging; neuropathology; prospective; racial difference; racial disparity; social culture; tau Proteins

SUMMARY Recent research diagnostic criteria for Alzheimer’s Disease require biomarker evaluation (as with neuroimaging and/or cerebrospinal fluid) of brain β Amyloid plaques, Tau tangles, and Neurodegeneration (A/T/N), enabling detection of the presence (or absence) of AD neuropathology in living individuals, and allowing AD to be diagnosed and staged while intervention maybe be feasible. The proposed supplement seeks to acquire prospective PET and MRI data in accordance with the NIH-sponsored SCAN protocols to classify individuals using the A/T/N framework, specifically for minority participants in the Mount Sinai ADRC Clinical Cohort to enable examination of racial disparities in the prevalence of A/T/N biomarkers and their association with cognition and other factors. Acquisition of A/T/N profiles in minority cohorts are of particular significance because dementia of the Alzheimer’s type disproportionately impacts minority populations (particularly African American and Hispanic populations in the United States). Despite higher prevalence rates among minorities, they are less likely to receive a diagnosis of Alzheimer’s disease or are more likely to be diagnosed later in the disease than their comparable non-minority counterparts. The proposed supplement seeks to help fill this gap by providing data on a minority that can be widely distributed among the Alzheimer’s disease research community. The cohort maintained by the Mount Sinai Alzheimer’s Disease Research Center is well-suited to examine racial disparities in imaging biomarkers given that over 40% of the cohort is comprised of minority participants. The supplement aims will: 1) establish the SCAN acquisition and data transfer protocols at our site and validate the on-site scanner, 2) acquire the SCAN protocol on a minority cohort of 40 participants at Mount Sinai sufficient to characterize individuals using the A/T/N framework, and 3) examine whether low prevalence of amyloidosis among memory-impaired minority participants can be explained by higher prevalence of tauopathy, neurodegeneration, or vascular burden. These aims have both practical and scientific significance and will result in data using the standardized SCAN protocol on an underserved population that can be widely shared and distributed to further Alzheimer’s disease research. Scientific significance will be achieved by comparing the data acquired through the supplement with non- minority participants characterized on SCAN-compatible protocols acquired with other resources to examine racial disparities in biomarker profiles.

摘要 最近阿尔茨海默病的研究诊断标准需要生物标记物的评估(如 神经影像和/或脑脊液)脑β淀粉样斑块、Tau缠结和神经变性 (A/T/N)，能够检测活着的个体中AD神经病理的存在(或不存在)，以及 允许AD的诊断和分期，而干预可能是可行的。拟议的补编 寻求根据NIH赞助的扫描协议获取预期的PET和MRI数据，以 使用A/T/N框架对个人进行分类，特别是针对西奈山刚果民主共和国的少数族裔参与者 临床队列能够检查A/T/N生物标记物及其患病率的种族差异 与认知等因素有关。在少数群体中获取A/T/N配置文件具有特殊意义 重要性，因为阿尔茨海默氏型痴呆症对少数族裔人群的影响不成比例 (特别是美国的非洲裔美国人和西班牙裔美国人)。尽管流行率更高 在少数族裔中，他们不太可能被诊断为阿尔茨海默病，或者更有可能被诊断为阿尔茨海默病 与其可比的非少数群体对应者相比，他们在疾病中诊断得更晚。拟议的补编 寻求通过提供可以在阿尔茨海默氏症患者中广泛分布的少数人的数据来帮助填补这一空白 疾病研究社区。西奈山阿尔茨海默病研究中心维持的队列 非常适合于检查成像生物标志物中的种族差异，因为超过40%的队列是 由少数族裔参与者组成。补充的目的是：1)建立扫描采集和数据 在我们的现场传输协议并验证现场扫描仪，2)在少数情况下获取扫描协议 在西奈山的40名参与者足以用A/T/N框架描述个人特征，以及3) 检查在记忆受损的少数民族参与者中淀粉样变性的低患病率是否可以 由较高的直肠畸形、神经退行性变或血管负担的发生率解释。这两个目标都有 具有实际和科学意义，并将产生使用标准化扫描协议的数据 服务不足的人群，可以广泛分享和分发，以进一步研究阿尔茨海默病。 通过将通过补充获得的数据与通过非补充获得的数据进行比较，将获得科学意义 少数参与者以与其他资源获得的扫描兼容协议为特征进行检查 生物标志物图谱中的种族差异。